Werner J Heinz

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6144344/publications.pdf

Version: 2024-02-01

70 papers	4,389 citations	126907 33 h-index	118850 62 g-index
74 all docs	74 docs citations	74 times ranked	4395 citing authors

#	Article	IF	Citations
1	Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet, The, 2016, 387, 760-769.	13.7	695
2	Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infectious Diseases, The, 2016, 16, 828-837.	9.1	528
3	Combination Antifungal Therapy for Invasive Aspergillosis. Annals of Internal Medicine, 2015, 162, 81-89.	3.9	376
4	Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. Annals of Hematology, 2016, 95, 1435-1455.	1.8	169
5	Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica, 2009, 94, 113-122.	3.5	160
6	Treatment of invasive fungal infections in cancer patientsâ€"updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Annals of Hematology, 2014, 93, 13-32.	1.8	143
7	Treatment of invasive fungal infections in cancer patientsâ€"Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Annals of Hematology, 2009, 88, 97-110.	1.8	128
8	Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses, 2011, 54, 279-310.	4.0	118
9	Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. European Journal of Cancer, 2009, 45, 2462-2472.	2.8	115
10	Cidofovir for BK Virusâ€"Associated Hemorrhagic Cystitis: A Retrospective Study. Clinical Infectious Diseases, 2009, 49, 233-240.	5.8	112
11	Clinical Performance of Aspergillus PCR for Testing Serum and Plasma: a Study by the European Aspergillus PCR Initiative. Journal of Clinical Microbiology, 2015, 53, 2832-2837.	3.9	105
12	Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agents. Haematologica, 2011, 96, 142-149.	3.5	99
13	Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica, 2013, 98, e127-e130.	3.5	99
14	Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies. Journal of Antimicrobial Chemotherapy, 2012, 67, 2260-2267.	3.0	85
15	Phase 1B Study of the Pharmacokinetics and Safety of Posaconazole Intravenous Solution in Patients at Risk for Invasive Fungal Disease. Antimicrobial Agents and Chemotherapy, 2014, 58, 3610-3617.	3.2	79
16	Rapid PCR Test for Discriminating between Candida albicans and Candida dubliniensis Isolates Using Primers Derived from the pH-Regulated PHR1 and PHR2 Genes of C. albicans. Journal of Clinical Microbiology, 1999, 37, 1587-1590.	3.9	75
17	Multicenter Comparison of Serum and Whole-Blood Specimens for Detection of Aspergillus DNA in High-Risk Hematological Patients. Journal of Clinical Microbiology, 2013, 51, 1445-1450.	3.9	74
18	Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (<scp>AGIHO</scp>). Mycoses, 2018, 61, 796-813.	4.0	69

#	Article	IF	Citations
19	Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an <scp>A</scp>spergillus <scp>PCR</scp> assay and a galactomannan <scp>ELISA</scp> in bronchoalveolar lavage samples. European Journal of Haematology, 2012, 89, 120-127.	2.2	63
20	Clinical evaluation of a Mucorales-specific real-time PCR assay in tissue and serum samples. Journal of Medical Microbiology, 2016, 65, 1414-1421.	1.8	62
21	Combined realâ€time <scp>PCR</scp> and galactomannan surveillance improves diagnosis of invasive aspergillosis in high risk patients with haematological malignancies. British Journal of Haematology, 2013, 161, 517-524.	2.5	61
22	Medical diagnostics for indoor mold exposure. International Journal of Hygiene and Environmental Health, 2017, 220, 305-328.	4.3	58
23	Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. Journal of Antimicrobial Chemotherapy, 2017, 72, 3406-3413.	3.0	58
24	Primary antifungal prophylaxis in leukaemia patients. European Journal of Cancer, Supplement, 2007, 5, 43-48.	2.2	57
25	Epidemiology ofCandidablood stream infections in patients with hematological malignancies or solid tumors. Medical Mycology, 2012, 50, 50-55.	0.7	57
26	Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis. Mycoses, 2013, 56, 304-310.	4.0	49
27	Population Pharmacokinetics of Liposomal Amphotericin B and Caspofungin in Allogeneic Hematopoietic Stem Cell Recipients. Antimicrobial Agents and Chemotherapy, 2012, 56, 536-543.	3.2	46
28	Treatment of invasive fungal diseases in cancer patientsâ€"Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Mycoses, 2020, 63, 653-682.	4.0	42
29	Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantationâ€"guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Annals of Hematology, 2012, 91, 1161-1174.	1.8	40
30	Pathogen-Specific DNA Enrichment Does Not Increase Sensitivity of PCR for Diagnosis of Invasive Aspergillosis in Neutropenic Patients. Journal of Clinical Microbiology, 2011, 49, 1267-1273.	3.9	39
31	Pharmacokinetics of Different Dosing Strategies of Oral Posaconazole in Patients with Compromised Gastrointestinal Function and Who Are at High Risk for Invasive Fungal Infection. Antimicrobial Agents and Chemotherapy, 2012, 56, 2652-2658.	3.2	39
32	Randomized Comparison of Safety and Pharmacokinetics of Caspofungin, Liposomal Amphotericin B, and the Combination of Both in Allogeneic Hematopoietic Stem Cell Recipients. Antimicrobial Agents and Chemotherapy, 2010, 54, 4143-4149.	3.2	38
33	Simultaneous Determination of Voriconazole and Posaconazole Concentrations in Human Plasma by High-Performance Liquid Chromatography. Antimicrobial Agents and Chemotherapy, 2009, 53, 3140-3142.	3.2	35
34	Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1281-1292.	2.5	35
35	High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid. Cancer Chemotherapy and Pharmacology, 2011, 68, 239-245.	2.3	34
36	Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn). Journal of Antimicrobial Chemotherapy, 2019, 74, 3315-3327.	3.0	30

#	Article	IF	Citations
37	A Comparison of Aspergillus and Mucorales PCR Testing of Different Bronchoalveolar Lavage Fluid Fractions from Patients with Suspected Invasive Pulmonary Fungal Disease. Journal of Clinical Microbiology, 2018, 56, .	3.9	28
38	A Novel Extraction Method Combining Plasma with a Whole-Blood Fraction Shows Excellent Sensitivity and Reproducibility for Patients at High Risk for Invasive Aspergillosis. Journal of Clinical Microbiology, 2012, 50, 2585-2591.	3.9	24
39	PGA4, a GAS homologue from Candida albicans, is up-regulated early in infection processes. Fungal Genetics and Biology, 2007, 44, 368-377.	2.1	20
40	Pharmacokinetics of chewed vs. swallowed raltegravir in a patient with AIDS and MAI infection: some new conflicting data. AIDS Research and Therapy, 2015, 12, 1.	1.7	20
41	Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma. European Journal of Endocrinology, 2016, 174, 343-353.	3.7	20
42	Clinical evidence for caspofungin monotherapy in the firstâ€line and salvage therapy of invasive <scp>A</scp>spergillus infections. Mycoses, 2016, 59, 480-493.	4.0	19
43	Relevance of Timing for Determination of Posaconazole Plasma Concentrations. Antimicrobial Agents and Chemotherapy, 2011, 55, 3621-3623.	3.2	17
44	Posaconazole plasma concentration in pediatric patients receiving antifungal prophylaxis after allogeneic hematopoietic stem cell transplantation. Medical Mycology, 2016, 54, 128-137.	0.7	17
45	Molecular responses to changes in the environmental pH are conserved between the fungal pathogens Candida dubliniensis and Candida albicans. International Journal of Medical Microbiology, 2000, 290, 231-238.	3.6	16
46	Abridged version of the AWMF guideline for the medical clinical diagnostics of indoor mould exposure. Allergo Journal International, 2017, 26, 168-193.	2.0	16
47	Diagnostic work up to assess early response indicators in invasive pulmonary aspergillosis in adult patients with haematologic malignancies. Mycoses, 2019, 62, 486-493.	4.0	16
48	Posaconazole plasma concentrations in pediatric patients receiving antifungal prophylaxis during neutropenia. Medical Mycology, 2016, 55, myw091.	0.7	13
49	Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicentre, open-label phase-II trial. Haematologica, 2021, 106, 543-554.	3.5	12
50	Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals. International Journal of Infectious Diseases, 2019, 83, 130-138.	3.3	10
51	Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole. Mycoses, 2018, 61, 868-876.	4.0	9
52	Impact of benzodiazepines on posaconazole serum concentrations. A population-based pharmacokinetic study on drug interaction. Current Medical Research and Opinion, 2012, 28, 551-557.	1.9	7
53	Aspergillusspecific nestedPCRfrom the site of infection is superior to testing concurrent blood samples in immunocompromised patients with suspected invasive aspergillosis. Mycoses, 2019, 62, 1035-1042.	4.0	7
54	Parathyroid-hormone-related-protein-associated hypercalcemia in a patient with CLL-type low-grade leukemic B-cell lymphoma. Haematologica, 2006, 91, ECR45.	3.5	7

#	Article	IF	Citations
55	Risk behaviours and viral infections among drug injecting migrants from the former Soviet Union in Germany: Results from the DRUCK-study. International Journal of Drug Policy, 2018, 59, 54-62.	3.3	6
56	Invasive fungal diseases in patients with new diagnosed acute lymphoblastic leukaemia. Mycoses, 2020, 63, 1101-1106.	4.0	6
57	Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 39-47.	1.9	5
58	Comment on: T2Candida MR as a predictor of outcome in patients with suspected invasive candidiasis starting empirical antifungal treatment: a prospective pilot study. Journal of Antimicrobial Chemotherapy, 2019, 74, 532-533.	3.0	3
59	Impact of patient education on plasma concentrations and effectiveness of posaconazole oral suspension under clinical conditions. Basic and Clinical Pharmacology and Toxicology, 2019, 124, 56-61.	2.5	2
60	A Phase III, Randomized, Double-Blind Trial to Evaluate Efficacy and Safety of Isavuconazole Versus Voriconazole in Patients with Invasive Mold Disease (SECURE): Outcomes in Hematopoietic Stem Cell Transplant Patients with Invasive Aspergillosis. Blood, 2014, 124, 1133-1133.	1.4	2
61	Utilisation, efficacy and safety of voriconazole: prospective, non-interventional study on treatment of IFIs in clinical practice. Current Medical Research and Opinion, 2011, 27, 335-342.	1.9	1
62	Therapeutic drug monitoring of antifungal agents. Laboratoriums Medizin, 2012, 36, 1-10.	0.6	0
63	Therapeutisches Drug Monitoring von Antimykotika/Therapeutic drug monitoring of antifungal agents. Laboratoriums Medizin, 2012, 36, .	0.6	0
64	HPLC method for the determination of the S- and R-diastereomers of telaprevir for treatment of patients with hepatitis C. Laboratoriums Medizin, 2015, 39, .	0.6	0
65	33. Pilzinfektionen in der Gastroenterologie. , 2017, , .		0
66	State of Medical Mycology at German Academic Medical Centres: A Survey of the Germanâ€Speaking Mycological Society (DMYKG) and the Paulâ€Ehrlichâ€Society for Chemotherapy (PEG). Mycoses, 2021, 64, 1177-1182.	4.0	0
67	Forty-One Recent Cases of Invasive Zygomycosis From a Global Clinical Registry.. Blood, 2009, 114, 4736-4736.	1.4	0
68	Investigation Of Fresh Tissue and Effusion Samples From Immunocompromised Hematologic Patients Suspected For Invasive Fungal Infection With An Aspergillus-specific PCR Is a Promising Tool For Identifying Invasive Aspergillosis. Blood, 2013, 122, 4552-4552.	1.4	0
69	Aspergillus Specific PCR and Galactomannan of Bronchoalveolar Lavage Are Superior to Concomitant Same-Day Testing of Concurrent Blood Samples in Immunocompromised Hematological Patients with Suspected Invasive Aspergillosis. Blood, 2015, 126, 2072-2072.	1.4	0
70	Pharmacokinetic Analysis during Antifungal Prophylaxis with Posaconazole Suspension in Pediatric and Adolescent Patients after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2015, 126, 4338-4338.	1.4	0